Nevertheless, the advent of precision medicine has led to substantial enhancements in the prognosis of patients with HER2-positive BC through the utilization of HER2-targeted therapies such as Trastuzumab (Herceptin®) [5]. This evidence concerns the gene ERBB2 and breast cancer.